PURPOSE: While microsurgical resection plays a central role in the management of ACMs, extensive surgery may be associated with substantial morbidity particularly for tumors in intimate association with critical structures. In this study, we evaluated the use of HFSRT in the management of ACM. MATERIALS AND METHODS: A total of 22 patients with ACM were treated using HFSRT. Frameless image guided volumetric modulated arc therapy (VMAT) was performed with a 6 MV linear accelerator (LINAC). The total dose was 25 Gy delivered in five fractions over five consecutive treatment days. Local control (LC) and progression free survival (PFS) rates were calculated using the Kaplan-Meier method. Common Terminology Criteria for Adverse Events, version 4.0 was used in toxicity grading. RESULTS: Out of the total 22 patients, outcomes of 19 patients with at least 36 months of periodic follow-up were assessed. Median patient age was 40 years old (range 24-77 years old). Median follow-up time was 53 months (range 36-63 months). LC and PFS rates were 100 and 89.4 % at 1 and 3 years, respectively. Only two patients (10.5 %) experienced clinical deterioration during the follow-up period. CONCLUSION: LINAC-based HFSRT offers high rates of LC and PFS for patients with ACMs.
PURPOSE: While microsurgical resection plays a central role in the management of ACMs, extensive surgery may be associated with substantial morbidity particularly for tumors in intimate association with critical structures. In this study, we evaluated the use of HFSRT in the management of ACM. MATERIALS AND METHODS: A total of 22 patients with ACM were treated using HFSRT. Frameless image guided volumetric modulated arc therapy (VMAT) was performed with a 6 MV linear accelerator (LINAC). The total dose was 25 Gy delivered in five fractions over five consecutive treatment days. Local control (LC) and progression free survival (PFS) rates were calculated using the Kaplan-Meier method. Common Terminology Criteria for Adverse Events, version 4.0 was used in toxicity grading. RESULTS: Out of the total 22 patients, outcomes of 19 patients with at least 36 months of periodic follow-up were assessed. Median patient age was 40 years old (range 24-77 years old). Median follow-up time was 53 months (range 36-63 months). LC and PFS rates were 100 and 89.4 % at 1 and 3 years, respectively. Only two patients (10.5 %) experienced clinical deterioration during the follow-up period. CONCLUSION: LINAC-based HFSRT offers high rates of LC and PFS for patients with ACMs.
Authors: Bruce E Pollock; Scott L Stafford; Andrew Utter; Caterina Giannini; Shawn A Schreiner Journal: Int J Radiat Oncol Biol Phys Date: 2003-03-15 Impact factor: 7.038
Authors: Stefanie Milker-Zabel; Peter Huber; Wolfgang Schlegel; Jürgen Debus; Angelika Zabel-du Bois Journal: J Neurooncol Date: 2009-04-01 Impact factor: 4.130
Authors: Omer Sager; Ferrat Dincoglan; Selcuk Demiral; Bora Uysal; Hakan Gamsiz; Esra Gumustepe; Fatih Ozcan; Onurhan Colak; Ahmet Tarik Gursoy; Cemal Ugur Dursun; Ahmet Oguz Tugcu; Galip Dogukan Dogru; Rukiyye Arslan; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu Journal: World J Exp Med Date: 2022-05-20
Authors: Jianmin Liu; Rafael Rojas; Fred C Lam; Farhan A Mirza; Anand Mahadevan; Ekkehard M Kasper Journal: Radiat Oncol Date: 2020-03-12 Impact factor: 3.481
Authors: Marcello Marchetti; Arjun Sahgal; Antonio A F De Salles; Marc Levivier; Lijun Ma; Ian Paddick; Bruce E Pollock; Jean Regis; Jason Sheehan; John H Suh; Shoji Yomo; Laura Fariselli Journal: Neurosurgery Date: 2020-10-15 Impact factor: 4.654